Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test
Posted
Frank Vinluan (via MedCity News)
Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small molecule had met the goal of a Phase 2 test in Becker muscular dystrophy, Servier said new results in a pivotal cohort do not show statistically significant benefit.
The post Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test appeared first on MedCity News.
